SynthesisMedicine2025
Efficacy and safety of Runzao Zhiyang capsules combined with antihistamines in the treatment of chronic eczema: A meta-analysis.
Synthesis in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis meta-analysis aims to evaluate the effects of Runzao Zhiyang capsules (RZC) plus antihistamines (AHs) for chronic eczema.
methodsA search involving 8 databases were conducted to collect studies on RZC with AHs for chronic eczema from inception to July 2024.
resultsThirty-two studies with 3071 participants were identified in this meta-analysis. Compared to the AHs group, the total effective rate of the RZC group was higher (relative risk [RR] = 1.30, 95% confidence interval [CI] = 1.24-1.36, P < .001) and a lower recurrence rate (RR = 0.33, 95% CI = 0.21-0.51, P < .001). The RZC group demonstrated better outcomes in the Eczema Area and Severity Index (mean difference [MD] = -1.44, 95% CI = -2.18 to -0.70, P < .001), severity of pruritus (MD = -0.24, 95% CI = -0.32 to -0.15, P < .001), and serum total IgE level (MD = -18.80, 95% CI = -25.20 to -12.40, P < .001). With respect to safety, the RZC group exhibited a reduced incidence of drowsiness (RR = 0.50, 95% CI = 0.28-0.87, P = .01), while the incidences of headache, dizziness, and gastrointestinal discomfort did not differ significantly from the AHs group (RR = 0.93, 95% CI = 0.46-1.90, P = .85); (RR = 1.41, 95% CI = 0.71-2.79, P = .32).
conclusionRZC when added to conventional AHs, further enhance the treatment efficacy for chronic eczema and significantly reduce the incidence of drowsiness.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.